Abstract
Although a large variety of pharmaceutical therapies for treating disease have been developed in recent years, there has been little progress in disease prevention. In particular, the protection of neural tissue is essential, because it is hardly regenerated. The use of nutraceuticals for maintaining the health has been supported by several clinical studies, including cross-sectional and interventional studies for age-related macular disease. However, mechanistic evidence for their effects at the molecular level has been very limited. In this review, we focus on lutein, which is a xanthophyll type of carotenoid. Lutein is not synthesized in mammals, and must be obtained from the diet. It is delivered to the retina, and in humans, it is concentrated in the macula. Here, we describe the neuroprotective effects of lutein and their underlying molecular mechanisms in animal models of vision-threatening diseases, such as innate retinal inflammation, diabetic retinopathy, and light-induced retinal degeneration. In lutein-treated mouse ocular disease models, oxidative stress in the retina is reduced, and its downstream pathological signals are inhibited. Furthermore, degradation of the functional proteins, rhodopsin (a visual substance) and synaptophysin (a synaptic vesicle protein also influenced in other neurodegenerative diseases such as Alzheimers disease and Parkinsons disease), the depletion of brain-derived neurotrophic factor (BDNF), and DNA damage are prevented by lutein, which preserves visual function. We discuss the possibility of using lutein, an antioxidant, as a neuroprotective treatment for humans.
Keywords: Oxidative stress, neuroprotection, lutein, retina, visual function, protein degradation, DNA damage, synaptophysin, BDNF, ubiqubiquitin proteasome system
Current Pharmaceutical Design
Title: Neuroprotective Effects of Lutein in the Retina
Volume: 18 Issue: 1
Author(s): Yoko Ozawa, Mariko Sasaki, Noriko Takahashi, Mamoru Kamoshita, Seiji Miyake and Kazuo Tsubota
Affiliation:
Keywords: Oxidative stress, neuroprotection, lutein, retina, visual function, protein degradation, DNA damage, synaptophysin, BDNF, ubiqubiquitin proteasome system
Abstract: Although a large variety of pharmaceutical therapies for treating disease have been developed in recent years, there has been little progress in disease prevention. In particular, the protection of neural tissue is essential, because it is hardly regenerated. The use of nutraceuticals for maintaining the health has been supported by several clinical studies, including cross-sectional and interventional studies for age-related macular disease. However, mechanistic evidence for their effects at the molecular level has been very limited. In this review, we focus on lutein, which is a xanthophyll type of carotenoid. Lutein is not synthesized in mammals, and must be obtained from the diet. It is delivered to the retina, and in humans, it is concentrated in the macula. Here, we describe the neuroprotective effects of lutein and their underlying molecular mechanisms in animal models of vision-threatening diseases, such as innate retinal inflammation, diabetic retinopathy, and light-induced retinal degeneration. In lutein-treated mouse ocular disease models, oxidative stress in the retina is reduced, and its downstream pathological signals are inhibited. Furthermore, degradation of the functional proteins, rhodopsin (a visual substance) and synaptophysin (a synaptic vesicle protein also influenced in other neurodegenerative diseases such as Alzheimers disease and Parkinsons disease), the depletion of brain-derived neurotrophic factor (BDNF), and DNA damage are prevented by lutein, which preserves visual function. We discuss the possibility of using lutein, an antioxidant, as a neuroprotective treatment for humans.
Export Options
About this article
Cite this article as:
Ozawa Yoko, Sasaki Mariko, Takahashi Noriko, Kamoshita Mamoru, Miyake Seiji and Tsubota Kazuo, Neuroprotective Effects of Lutein in the Retina, Current Pharmaceutical Design 2012; 18 (1) . https://dx.doi.org/10.2174/138161212798919101
DOI https://dx.doi.org/10.2174/138161212798919101 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Ionic Liquid as a Green Media for the One-Pot Synthesis of New α- Thiazolodepsipeptide Derivatives via a Four-Component Reaction
Letters in Organic Chemistry Bacterial Conjunctivitis in Childhood: Etiology, Clinical Manifestations, Diagnosis, and Management
Recent Patents on Inflammation & Allergy Drug Discovery Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Flavonoids and Anthranquinones as Xanthine Oxidase and Monoamine Oxidase Inhibitors: A New Approach Towards Inflammation and Oxidative Stress
Current Topics in Medicinal Chemistry Adverse Events of Proton Pump Inhibitors: Potential Mechanisms
Current Drug Metabolism Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Risk Factors of Preeclampsia among Pregnant Women in Khorramabad (West of Iran)
Current Women`s Health Reviews PARADIGM - HF: The Rise of the Arnis
Reviews on Recent Clinical Trials Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review
Current Hypertension Reviews Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation in Atherosclerosis: A New Therapeutic Target
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews Candesartan Cilexetil Microemulsions for Transdermal Delivery: Formulation, in-vitro Skin Permeation and Stability Assessment
Current Drug Delivery Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Licofelone-A Novel Analgesic and Anti-Inflammatory Agent
Current Topics in Medicinal Chemistry Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery